NTx 428 regimen - Stem Cell Therapeutics

Drug Profile

NTx 428 regimen - Stem Cell Therapeutics

Alternative Names: Erythropoeitin + hCG; Erythropoeitin + prolactin; hCG + erythropoeitin; NTx-428; Prolactin + erythropoeitin

Latest Information Update: 16 Jun 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Stem Cell Therapeutics Corp.
  • Developer Trillium Therapeutics Inc
  • Class Erythropoietins; Peptide hormones
  • Mechanism of Action Cell differentiation stimulants; Nerve growth factor stimulants; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Brain injuries

Most Recent Events

  • 02 Jun 2014 Stem Cell Therapeutics is now called Trillium Therapeutics
  • 25 Jul 2013 Discontinued - Phase-II for Brain injuries in Canada (Parenteral)
  • 25 Jul 2013 Stem Cell Therapeutics' NTx 428 regimen is available for licensing as of 25 Jul 2013. http://www.stemcellthera.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top